Skip to content Skip to menu

Medicines Australia welcomes new AusBiotech CEO

Thursday, 3 May 2018

Media Release

Medicines Australia (MA) congratulates Lorraine Chiroiu on her appointment to CEO of AusBiotech.  After eight years with AusBiotech in various roles, most recently as Deputy CEO, Ms Chiroiu is extremely well qualified to lead the organisation in its continuing representation of the life sciences industry.

Interim CEO of MA, Ms Elizabeth de Somer said, “I look forward to working with Lorraine to continue, and strengthen, the collaboration between our organisations.  Lorraine will be an excellent voice for the biotechnology industry while her experience means the sector is in good hands.”

MA thanks Mr Glenn Cross, CEO of AusBiotech since 2016, for working constructively and openly with MA on a range of issues impacting both the life sciences and innovative medicines sectors.

Ms de Somer also said, “Under Glenn’s direction, both our organisations have constructively worked in parallel on common issues such as Intellectual Property rights, promoting Australia as a destination for clinical trials, and data protection for biologic medicines.  I wish Glenn success with his future.”

-END-

CONTACT: Kim Bessell

Ph. 0423 781 291

Email: kbessell@medaus.com.au

 

Top